Heparin Sodium Injection Shortage: Current FDA Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Heparin Sodium Injection is currently listed in shortage status by the FDA, affecting some manufacturers, with details on availability provided.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 8, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Heparin Sodium Injection.
What's in Shortage
The generic drug Heparin Sodium Injection, also known by brand names HEPARIN SODIUM and HEPARIN SODIUM IN SODIUM CHLORIDE, is in a current shortage status. It is an injection with a therapeutic category in hematology. The shortage was first posted on 11/14/2017 and last updated on 04/02/2026.
Which Manufacturers Are Affected
- Fresenius Kabi USA, LLC: Available for presentations Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77) and Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10). Related info: Check wholesalers for inventory. Contact info: 888-386-1300.
- Hospira, Inc., a Pfizer Company: Available for presentations Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59) and Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03). Contact info: 844-646-4398.
- Baxter Healthcare: Available for presentation Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03). Unavailable for presentation Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18) due to product discontinuation. Contact info: 888-229-0001.
Why There's a Shortage
No specific reason was provided in the source data for this shortage.
What Patients Should Do
Patients experiencing issues with obtaining Heparin Sodium Injection should talk to their pharmacist about availability and options. They may also contact the relevant manufacturer using the provided contact information. Remember, patients should consult their healthcare provider for any guidance on their treatment; this article does not provide medical advice.
Source
Information from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,721 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 8, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.